Advertisement

Chirurgisches Outcome bei Colitis ulcerosa in der Biologika-Ära

  • C. HolmerEmail author
Journal Club
  • 5 Downloads

Originalpublikation

Abelson JS, Michelassi F, Mao J, Sedrakyan A, Yeo H (2018) Higher Surgical Morbidity for Ulcerative Colitis Patients in the Era of Biologics. Ann Surg 268:311–317

Hintergrund und Ziel.

Die Behandlung mit Biologika hat seit der Zulassung von Infliximab durch die amerikanische Food and Drug Administration drastisch zugenommen. Die Studienlage hinsichtlich des Einflusses dieser Wirkstoffe auf das chirurgische Outcome ist weiterhin kontrovers. Ziel dieser Studie war es, Unterschiede im chirurgischen Ansatz und postoperativen Outcome von Patienten mit Colitis ulcerosa vor und nach Einführung der Biologikatherapie zu analysieren.

Methodik.

Anhand einer nationalen Datenbank (New York State Department of Health Statewide Planning and Research Cooperative System all-age-group, all-payer database) wurden Patienten identifiziert, bei denen zwischen 1995 und 2013 aufgrund einer Colitis ulcerosa eine Operation erfolgte. Verglichen wurden die Ergebnisse für die Indexaufnahme...

Surgical outcome for ulcerative colitis patients in the era of biologics

Notes

Interessenkonflikt

C. Holmer gibt an, dass kein Interessenkonflikt besteht.

Literatur

  1. 1.
    Kirchgesner J, Lemaitre M, Rudnichi A, Racine A, Zureik M, Carbonell F, Dray-Spira R (2017) Therapeutic management of inflammatory bowel disease in real-life practice in the current era of antiTNF agents: analysis of the French administrative health database 2009–2014. Aliment Pharmacol Ther 45(1):37–49CrossRefGoogle Scholar
  2. 2.
    Paramsothy S, Rosenstein AK, Mehandru S, Colombel JF (2018) The current state of the art for biological therapies and new small molecules in inflammatory bowel disease. Mucosal Immunol 11:1558–1570CrossRefGoogle Scholar
  3. 3.
    Mor IJ, Vogel JD, da Luz Moreira A, Shen B, Hammel J, Remzi FH (2008) Infliximab in ulcerative colitis is associated with an increased risk of postoperative complications after restorative proctocolectomy. Dis Colon Rectum 51:1202–1207CrossRefGoogle Scholar
  4. 4.
    Selvasekar CR, Cima RR, Larson DW, Dozois EJ, Harrington JR, Harmsen WS, Loftus EV Jr, Sandborn WJ, Wolff BG, Pemberton JH (2007) Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204:956–962CrossRefGoogle Scholar
  5. 5.
    Pandey S, Luther G, Umanskiy K, Malhotra G, Rubin MA, Hurst RD, Fichera A (2011) Minimally invasive pouch surgery for ulcerative colitis: is there a benefit in staging? Dis Colon Rectum 54:306–310CrossRefGoogle Scholar
  6. 6.
    Hicks CW, Hodin RA, Bordeianou L (2013) Possible overuse of 3‑stage procedures for active ulcerative colitis. JAMA Surg 148:658–664CrossRefGoogle Scholar
  7. 7.
    Ferrante M, D’hoore A, Vermeire S, Declerck S, Noman M, van Assche G, Hoffman I, Rutgeerts P, Penninckx F (2009) Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis 15:1062–1070CrossRefGoogle Scholar
  8. 8.
    Geltzeiler CB, Lu KC, Diggs BS, Deveney KE, Keyashian K, Herzig DO, Tsikitis VL (2014) Initial surgical management of ulcerative colitis in the biologic era. Dis Colon Rectum 57:1358–1363CrossRefGoogle Scholar
  9. 9.
    Bikhchandani J, Polites SF, Wagie AE, Habermann EB, Cima RR (2015) National trends of 3‑ versus 2‑stage restorative proctocolectomy for chronic ulcerative colitis. Dis Colon Rectum 58:199–204CrossRefGoogle Scholar
  10. 10.
    Narula N, Charleton D, Marshall JK (2013) Meta-analysis: peri-operative anti-TNFa treatment and post-operative complications in patients with inflammatory bowel disease. Aliment Pharmacol Ther 37:1057–1064CrossRefGoogle Scholar
  11. 11.
    Nørgård BM, Nielsen J, Qvist N, Gradel KO, de Muckadell OB, Kjeldsen J (2012) Pre-operative use of anti-TNF-a agents and the risk of post-operative complications in patients with ulcerative colitis—a nationwide cohort study. Aliment Pharmacol Ther 35:1301–1309CrossRefGoogle Scholar
  12. 12.
    Selvaggi F, Pellino G, Canonico S, Sciaudone G (2015) Effect of preoperative biologic drugs on complications and function after restorative proctocolectomy with primary ileal pouch formation: systematic review and meta-analysis. Inflamm Bowel Dis 21:79–92CrossRefGoogle Scholar
  13. 13.
    Kulaylat AS, Kulaylat AN, Schaefer EW, Tinsley A, Williams E, Koltun W, Hollenbeak CS, Messaris E (2017) Association of preoperative anti-tumor necrosis factor therapy with adverse postoperative outcomes in patients undergoing abdominal surgery for ulcerative colitis. JAMA Surg 152(8):e171538CrossRefGoogle Scholar
  14. 14.
    Ferrante M, de Buck van Overstraeten A, Schils N, Moens A, van Assche G, Wolthuis A, Vermeire S, D’Hoore A (2017) Perioperative use of vedolizumab is not associated with postoperative infectious complications in patients with ulcerative colitis undergoing colectomy. J Crohns Colitis 11:1353–1361CrossRefGoogle Scholar
  15. 15.
    Lightner AL, McKenna NP, Moncrief S, Pemberton JH, Raffals LE, Mathis KL (2017) Surgical Outcomes in Vedolizumab-Treated Patients with Ulcerative Colitis. Inflamm Bowel Dis 23(12):2197–2201CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  1. 1.Klinik für Allgemein- und ViszeralchirurgieSt. Joseph Krankenhaus Berlin TempelhofBerlinDeutschland

Personalised recommendations